Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of SB3 (trastuzumab biosimilar) + ramucirumab + paclitaxel in HER2-positive metastatic gastric cancer after failure of first-line therapy
KCT0003638Phase 2Withdrawn
- Sponsor
- Daewoong Pharmaceutical
- Start
- Mar 2019
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of trastuzumab-dttb, ramucirumab, paclitaxel in gastric cancer (GC), sponsored by Daewoong Pharmaceutical. Planned start Mar 2019; status: withdrawn.
02
Drugs
trastuzumab-dttbramucirumabpaclitaxel
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on KCT0003638.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0003638.